What is EGRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for EGRX?

P/E (TTM) is 1.04 and 52-week range is $0.00 to $2.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s EGRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for EGRX?

The company profile lists revenue (TTM) near $253M, net income (TTM) near $12M, EPS (TTM) near $0.92 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Eagle Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Woodcliff Lake, New Jersey, US, 13M shares outstanding, ISIN US2697961082 when available from company profile and filing metadata.

Eagle Pharmaceuticals Inc

$EGRX

Health Care · Biotechnology

IR Run Scenarios

$0.97

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.

Employees

134

Website

www.eagleus.com/

IPO

2014-02-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)